Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics
Paclitaxel 30 mg/m2 twice/week Trastuzumab 4mg/kg, loading dose, then 2 mg/kg weekly and Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
**Surgery: Patients will undergo lumpectomy and axillary node dissection or modified radical mastectomy within two months following discontinuation of pre-operative systemic therapy, contingent upon recovery of skin toxicity. Pathologic response will be evaluated at the time of surgery. Additional tissue samples will be collected from the surgical specimen for assessment of tumor molecular characteristics.
***All patients may undergo four cycles of post-operative Standard AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) or four cycles of post-operative epirubicin and Cyclophosphamide (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) if doxorubicin is not available Tamoxifen as well or any alternative antihormonal therapy may be prescribed for five years for patients with hormone receptor positive tumors. Herceptin (Trastuzumab) will be prescribed for a total of 1 year since first dose as per standard of care.
研究概览
详细说明
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
New York
-
New York、New York、美国、10065
- Weill Medical College of Cornell University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Biopsy proven locally advanced breast cancer: STAGE IIB (T must be > 3.0 cm, N0), IIIA (T0N2, T1N2, T2N2, T3N1), IIIB (T4N0-2).
- HER-2/neu positive ( DAKO 3+ by Immunohistochemistry or FISH positive if Dako 2+)
- Metastatic breast cancer: limited to the subset of patients with intact breast, locally advanced tumor and involved ipsilateral supraclavicular nodes.
- Measurable disease required according to the RECIST criteria (Response Evaluation Criteria in Solid Tumors)
- Adequate laboratory values:
- Hgb > 10
- ANC(Absolute Neutrophil Count) > 1500
- Platelets > 150,000
- Cr < 1.5
- Liver function < 3 X normal.
- Patient > 18 years of age.
- Medically and psychologically able to comply with all study requirements.
- ECOG (Eastern cooperative Oncology group) performance score 0-1.
- Signed informed consent.
Exclusion Criteria:
- Stage 0, Stage I, Stage IIA.
- Previous XRT(Radiation therapy) or chemotherapy.
- Presence of distant metastases documented clinically or radiographically with the exception of ipsilateral supraclavicular nodes.
- Inflammatory breast cancer.
- Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-fluorouracil.
- Exclude pregnant or lactating woman.
- Woman of childbearing potential with either a positive or no pregnancy test at baseline.
- Woman of childbearing potential not using a reliable and appropriate contraceptive method.
- (Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential).
- Patient will agree to continue contraception for 30 days from the date of the last study drug administration.
- Serious concurrent infections.
- Clinically significant cardiac disease not well controlled with medication (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias ) or myocardial infarction within the last 12 months.
- Patients who have had an organ allograft.
- Patients with severe renal impairment (creatinine clearance below 30 mL/min [Cockcroft and Gault43]). In patients with moderate renal impairment (creatinine clearance 30-50 mL/min [Cockcroft and Gault43]) at baseline, a dose reduction to 75% of the XELODA starting dose is recommended. In patients with mild renal impairment (creatinine clearance 51-80 mL/min) no adjustment in starting dose is recommended.
- In phase I studies, those with any abnormal renal function, since toxicity will likely be affected by the presence of any significant renal dysfunction.
- Cockcroft and Gault Equation:
- (140 - age [yrs]) (body wt [kg])
- Creatinine clearance for males = --------------
- (72) (serum creatinine [mg/dL])
- Creatinine clearance for females = 0.85 x male value
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm 1 Capecitabine and RT
Her-2/neu negative patients will be given Capecitabine (xeloda, 750mg/m2 twice daily orally.
Treatment should begin on day 1 of radiation therapy.
The two doses should be taken about 30 minutes after eating (eg.
after breakfast and after dinner).
Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
|
Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor.
At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally.
Treatment should begin on day 1 of radiation therapy.
The two doses should be taken about 30 minutes after eating (eg.
after breakfast and after dinner).
Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
其他名称:
|
|
实验性的:Arm 2 Paclitaxel/Trastuzumab and RT
Trastuzumab (Herceptin®) will begin on day 1 of radiation therapy and be administered weekly to Her-2/neu Positive patients.
The first dose will be 4mg/kg given IV over 90 minutes.
Weekly doses will be 2 mg/kg/week IV over 30 minutes.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
|
Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor.
At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel.
The first dose will be 4mg/kg given IV over 90 minutes.
Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes.
The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
其他名称:
Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose.
If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses.
Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
其他名称:
|
|
实验性的:Arm 3: Paclitaxel and RT
Paclitaxel 30 mg/m2 twice per week given IV over 1 hour to Her-2/neu negative patients.
Treatment will be initiated during the first week of radiation therapy and should be administered on a Monday/Thursday or Tuesday/Friday schedule.
|
Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor.
At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose.
If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses.
Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
其他名称:
|
|
实验性的:Arm 4: Paclitaxel/Trastuzumab and RT
Trastuzumab (Herceptin®) tx will be administered weekly, together with one of the 2 weekly doses of Paclitaxel to Her-2/neu Positive patients.
The 1st dose will be 4mg/kg given IV over 90 minutes.
Weekly doses will b given at a dose of 2 17mg/kg/week IV over 30 minutes.
The Tx with Trastuzumab will continue weekly after the completion of the radiation tx until surgery & thereafter as per std of care up to 1 yr post surgery.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
Tx will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
|
Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor.
At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel.
The first dose will be 4mg/kg given IV over 90 minutes.
Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes.
The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
其他名称:
Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose.
If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses.
Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Feasibility & Efficacy of Chemo-radiation While Targeting Treatment, Based on: Original Tumor Characteristics; to be Followed by [Need for] Conventional Post-operative Chemotherapy
大体时间:12/2014 (up to 12 years)
|
12/2014 (up to 12 years)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To Assess the Pathological Response Rate and Compare it to That Achieved in Our Previous Phase I-II Trials of Concurrent Chemo-radiation.
大体时间:12/2014 (up to 12 years)
|
No data displayed because Outcome Measure has zero total participants analyzed.
|
12/2014 (up to 12 years)
|
|
To Store Core Biopsies of the Original Tumor Before and After Treatment (From the Surgical Specimen) for Future Molecular Biology Studies in LABC.
大体时间:12/2014 (up to 12 years)
|
No data displayed because Outcome Measure has zero total participants analyzed.
|
12/2014 (up to 12 years)
|
|
To Acquire Descriptive Information on Patient Adherence to Therapy and on Quality of Life During Treatment.
大体时间:12/2014 (up to 12 years)
|
Data were not collected as PI left institution prior to enrollment completion.
Planned Statistical analysis was not performed for this secondary outcome measure.
|
12/2014 (up to 12 years)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.